CSNK1A1 and myelodysplastic syndrome: Interestingly, lenalidomide, found particularly effective for promoting cytogenetic and clinical long‐term remission in del(5q) MDS, targets CSNK1A1 for E3 ubiquitin ligase‐mediated ubiquitination and degradation [129].